Press release - 02/04/2011 Nanosensor detects pathogens Researchers from the Stuttgart-based Max Planck Institute of Solid State Research have succeeded in detecting tiny traces of DNA using sensors made from carbon nanotubes. The sensors are highly selective for specific DNA sequences and it is envisaged that they will be used for the rapid examination of blood samples.https://www.gesundheitsindustrie-bw.de/en/article/press-release/nanosensor-detects-pathogens
Press release - 10/03/2011 Novel High-Resolution Methods in Fluorescence Microscopy Heidelberg scientists have developed a new method by which the physical limits in high-resolution light microscopy can be overcome with the aid of chemical reactions. The scientists replaced light-dependent processes by chemical reactions for light-independent switching of fluorescent probes to mark cellular structures for high-resolution optical microscopy. This method opens up new application vistas for fluorescence microscopy.https://www.gesundheitsindustrie-bw.de/en/article/press-release/novel-high-resolution-methods-in-fluorescence-microscopy
Article - 07/03/2011 Thomas Brunner: steroid synthesis in the intestine A research team led by Prof. Dr. Thomas Brunner at the University of Konstanz has found out that intestinal epithelial cells are able to synthesise anti-inflammatory steroids glucocorticoids following immunological stress which makes a considerable contribution to the maintenance of local immune homoeostasis. Brunner plans to use his findings to develop a therapeutic approach for the treatment of inflammatory bowel diseases.https://www.gesundheitsindustrie-bw.de/en/article/news/thomas-brunner-steroid-synthesis-in-the-intestine
Article - 06/03/2011 Heidelberg Translational Lung Research Centre University and non-university research institutions in Heidelberg that carry out research into lung diseases have established an expert network – the Heidelberg Translational Lung Research Centre – which is part of the new BMBF-funded German Centre for Lung Research. In Heidelberg, research focuses on the development and treatment of cystic fibrosis, chronic obstructive pulmonary diseases and lung cancer. https://www.gesundheitsindustrie-bw.de/en/article/news/heidelberg-translational-lung-research-centre
Press release - 02/03/2011 immatics appoints Dr. Harald Stock to its Board immatics biotechnologies GmbH, a late-stage biopharmaceutical company developing therapeutic vaccines that are active against cancer, today announced the appointment of Dr. Harald F. Stock to the board of directors, effective February 2011.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-appoints-dr-harald-stock-to-its-board
Press release - 28/02/2011 Heidelberg "start-up" wins the German Industry’s Innovation Award 2010 PEPperPRINT GmbH has won the 2010 German Industry’s Innovation Award in the category “Start-Up Companies”. The Heidelberg-based biotechnology company was awarded the prize by the German Minister of Education and Research, Dr. Annette Schavan, at a German industry festive event recently held in the Frankfurt Congress Centre. https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-start-up-wins-the-german-industry-s-innovation-award-2010
Article - 26/02/2011 Researchers from Ulm identify congenital genetic defect Researchers led by the Ulm paediatrician Holger Cario have identified a rare, congenital genetic defect that leads to the dysregulation of the folic acid metabolism, resulting in aenemia, epilepsy and learning difficulties in children. All aspects of the disease can be treated quite successfully with the exception of the cramps associated with the defect.https://www.gesundheitsindustrie-bw.de/en/article/news/researchers-from-ulm-identify-congenital-genetic-defect
Dossier - 07/02/2011 The era of personalised medicine is dawning A promising future does not easily disappear into thin air. This is certainly the case with the vision of personalised medicine. For many years, biomedical researchers have vaunted the potential benefits of their findings despite the fact that neutral observers do not think that personalised medicine will really take off within the next 15 or 20 years. Moreover personalised medicine is a controversial term. So what is the state of play right now?https://www.gesundheitsindustrie-bw.de/en/article/dossier/the-era-of-personalised-medicine-is-dawning
Article - 07/02/2011 The discovery of the individual as business model The move towards personalised medicine has made considerable progress, in particular in the field of oncology, where it is leading to the close integration of diagnostics and therapy as well as to the development of profitable new business models, some of which have controversial exclusive legal claims.https://www.gesundheitsindustrie-bw.de/en/article/news/the-discovery-of-the-individual-as-business-model
Press release - 26/01/2011 Uncovering the Genetics of Prostate Cancer Germany will contribute another project to the International Cancer Genome Consortium ICGC. Coordinated by the German Cancer Research Center and the University Medical Center Hamburg-Eppendorf physicians and molecular biologists will now start to investigate the genetic causes of early prostate cancer. https://www.gesundheitsindustrie-bw.de/en/article/press-release/uncovering-the-genetics-of-prostate-cancer-1
Press release - 19/01/2011 Colonoscopy Provides Protection from Cancer on Both Sides of the Colon Scientists of the German Cancer Research Center DKFZ in Heidelberg have now shown that inspection of both sides of the colon also reduces cancer risk in the right part of the colon by more than 50 percent. The overall risk was found to be 77 percent lower. This means that colonoscopy provides very good protection from colon cancer - even though it is not a 100 percent guarantee.https://www.gesundheitsindustrie-bw.de/en/article/press-release/colonoscopy-provides-protection-from-cancer-on-both-sides-of-the-colon
Article - 29/11/2010 CYP2D6 and the oestrogen receptor The medicinal adjuvant therapy of breast cancer is a good example of how important it is being aware that different patients metabolise drugs differently. This knowledge plays a key role in the prescription of effective drugs at the correct dose and in preventing adverse reactions and interactions with concomitant drugs.https://www.gesundheitsindustrie-bw.de/en/article/news/cyp2d6-and-the-oestrogen-receptor
Press release - 25/11/2010 BD Diagnostics and Lonza Collaborate BD Diagnostics, a segment of BD (Becton, Dickinson and Company), and Lonza Group Ltd announced today that they have entered into an exclusive licensing and collaboration agreement for Lonza to commercialize its microCompass™ molecular assays on the BD MAX™ System.https://www.gesundheitsindustrie-bw.de/en/article/press-release/bd-diagnostics-and-lonza-collaborate
Press release - 16/11/2010 Summit conference on regional development in the Rhine-Neckar Metropolitan Region To learn from leading regional developers this was the goal set by the representatives of the Biotechnology Cluster Rhine-Neckar BioRN for the Regional Development Summit. Representatives from business science and politics in the Rhine-Neckar Metropolitan Region met in the Villa Bosch in Heidelberg on November 11 with experts from the leading international high-tech sites in Leuven Belgium Cambridge UK and Israel. https://www.gesundheitsindustrie-bw.de/en/article/press-release/summit-conference-on-regional-development-in-the-rhine-neckar-metropolitan-region
Press release - 15/11/2010 ASPEX- an advanced Schizosaccharomyces expression system The ASPEX system Asahi Glass Schizosaccharomyces Expression is a full-scale contract manufacturing service for recombinant proteins with up to the 3000 L scale. It is based on S. pombe an endotoxin-free fission yeast isolated from east African beer. Examples for gene expressions in the ASPEX system are manifold. The dedicated production facility located close to the Research Center is organized under cGMP rules and thus enables supply of…https://www.gesundheitsindustrie-bw.de/en/article/press-release/aspex-an-advanced-schizosaccharomyces-expression-system
Article - 13/11/2010 Franz Porzsolt is turning existing beliefs and dogmas on their head Porzsolt a 64-year-old clinical economist specialist in internal medicine and oncologist enjoys turning accepted truths on their head. Many colleagues regard him as an outspoken critic of others for his tendency to refer to science as theory and clinical settings as practice. Porzsolt criticises evidence-based medicine as it is currently understood and applied.https://www.gesundheitsindustrie-bw.de/en/article/news/franz-porzsolt-is-turning-existing-beliefs-and-dogmas-on-their-head
Article - 05/11/2010 DITABIS: Custom-made analysis systems for research and industry Outstanding quality, clever product design, flexibility and rapid implementation make Pforzheim-based DITABIS Digital Biomedical Imaging Systems AG a true racing stable for device developments. The company’s key competences include imaging plate technology and fluorescence scanning, procedures that can be used to record high-resolution digital images in a contrast-rich and highly linear way. The innovative imaging systems are predominantly used…https://www.gesundheitsindustrie-bw.de/en/article/news/ditabis-custom-made-analysis-systems-for-research-and-industry
Press release - 04/11/2010 LifeCodexx Appoints Head of Commercial Operations Dr. Martin Burow, a proven expert in the field of prenatal diagnostics, has joined the LifeCodexx team as Head of Commercial Operations.https://www.gesundheitsindustrie-bw.de/en/article/press-release/lifecodexx-appoints-head-of-commercial-operations
Article - 25/10/2010 Angelika Rück visualises the dance of molecules Angelika Rück measures the luminescence time of molecules in order to find out whether proteins are speaking with each other. She hopes that she will soon be able to differentiate inflammation from tumours. Rück who is head of microscopy at the Ulm-based ILM has worked hard with her colleagues to make the Eselsberg-based Ulm University location one of southern Germanys leading life cell imaging centres.https://www.gesundheitsindustrie-bw.de/en/article/news/angelika-rueck-visualises-the-dance-of-molecules
Article - 18/10/2010 DNA analysis is becoming more automated GATC Biotech AG is already on the lookout for next generation sequencing technologies in the form of real-time single-molecule sequencing. In an interview with BIOPRO Thomas Pohl CTO of GATC Biotech AG explains why the company is continuously expanding its existing equipment with the latest global technologies.https://www.gesundheitsindustrie-bw.de/en/article/news/dna-analysis-is-becoming-more-automated
Dossier - 18/10/2010 New machines for the life sciences Hardware and software applications have become an integral part of the everyday life of life sciences researchers, developers and service providers. It is impossible to imagine life science applications without effective hardware and software applications – from computer-assisted drug screening to the automatic production of biosensors for rapid, mobile, purse-size bacterial test devices. Trends such as automation and miniaturisation lead to ever…https://www.gesundheitsindustrie-bw.de/en/article/dossier/new-machines-for-the-life-sciences
Press release - 13/10/2010 GATC Biotech to be First European Service Provider for the PacBio RS GATC Biotech announced today that it has agreed to purchase the PacBio RS platform, a single molecule, real-time (SMRT™) sequencing technology. The new PacBio RS will be the fifth sequencing technology for GATC Biotech. The system is planned for installation in early 2011.https://www.gesundheitsindustrie-bw.de/en/article/press-release/gatc-biotech-to-be-first-european-service-provider-for-the-pacbio-rs
Article - 04/10/2010 Dr. Kerstin Stemmer: important approaches for the early identification of carcinogenic substances Dr. Kerstin Stemmer from the University of Konstanz has found a way to identify the carcinogenic potential of substances in just a few days using state-of-the-art technology and new investigation methods. This is the first time that researchers have been able to reduce the time and the number of animals used in carcinogenesis studies.https://www.gesundheitsindustrie-bw.de/en/article/news/dr-kerstin-stemmer-important-approaches-for-the-early-identification-of-carcinogenic-substances
Press release - 21/09/2010 The National Cohort study The objective of the National Cohort study, the largest prospective study ever conducted in Germany, is to provide answers to a broad range of epidemiological questions, to identify risk factors for common diseases and to open up new treatment pathways. This project is being planned since beginning 2009 by the health centers of the Helmholtz Association in a network with partners from universities and other public research institutions.https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-national-cohort-study
Dossier - 20/09/2010 Neurodegenerative diseases It is estimated that around 1.2 million people in Germany suffer from dementia, and around 200,000 people are diagnosed with neurodegenerative diseases every year. It is expected that by 2050, one in three people in Germany will be over 60 and the number of age-related diseases, particularly dementias, for which no effective curative therapy is currently available, will increase considerably. Given the large numbers of elderly people and…https://www.gesundheitsindustrie-bw.de/en/article/dossier/neurodegenerative-diseases